Dipna Pharmachem Ltd

Dipna Pharmachem Ltd has announced that its Board of Directors will convene on July 1, 2026, at 4:00 PM IST. The meeting, to be held at the company's registered office in Ahmedabad, will primarily focus on considering and approving the Audited Financial Results for the half-year and full-year ended March 31, 2026, along with the Auditor's Report. The agenda also allows for discussion of any other matters with the Chairperson's permission. This meeting is crucial for the company to finalize and disclose its financial performance for the preceding fiscal period.

Dipna Pharmachem Ltd's board, in its meeting on April 22, 2026, appointed M/s. Jay Pandya & Associates as the Secretarial Auditor for the financial year 2025-26, subject to shareholder approval. The board also approved a notice for a postal ballot via electronic means for member approval. The e-voting period is scheduled from April 23, 2026, to May 22, 2026.

The Board of Directors of Dipna Pharmachem Ltd, in its meeting held on April 22, 2026, recommended the appointment of M/s. Jay Pandya & Associates as the Secretarial Auditor for the financial year 2025-26. This appointment is subject to the approval of the company's shareholders. Additionally, the Board approved the Notice of Postal Ballot for obtaining shareholder consent through remote e-voting, which will commence on April 23, 2026, and conclude on May 22, 2026. The auditor appointment is to comply with the Companies Act, 2013 and SEBI Listing Regulations.

Dipna Pharmachem Ltd has clarified that there is no price sensitive or material information that has resulted in the significant movement of its stock price. The company has made all required disclosures under SEBI regulations and there is no event or announcement that needs to be reported. The volatility in the stock price is attributed to natural and market-driven factors.

Dipna Pharmachem Ltd has announced the closure of the trading window for purchasing, selling, or dealing in the company's equity shares. The trading window will be closed for all directors, promoters, designated persons, and insiders from April 1, 2026, until 48 hours after the declaration and publication of the audited financial results for the year ending on March 31, 2026. This decision has been made in accordance with Clause 4 of Schedule B of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Practices, Procedure and Conduct to Regulate, Monitor and Report Trading by Insiders.

Dipna Pharmachem Ltd has received trading approval from BSE Limited for 22,44,000 fully paid-up equity shares. These shares are being issued at a premium of Rs. 3.05/- each to non-promoters on a preferential basis pursuant to the conversion of warrants. The approval was received in reference to the in-principle application submitted by the Company on 13 March 2025 for the issuance of Convertible Warrants on a preferential basis.

Dipna Pharmachem Ltd has clarified that there is no price sensitive or material information that has resulted in the significant movement of their stock price. The company has made all required disclosures under the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. There is currently no event or information that needs to be reported to the Stock Exchange. The volatility in the price of the company’s script on the Stock Exchange is natural and market-driven.

Dipna Pharmachem Ltd has allotted 22,44,000 equity shares pursuant to the conversion of 22,44,000 convertible warrants. The allotment was made to Mr. Ashok Dilipkumar Jain and Ms. Kajal Ashok Jain, who belong to the non-promoter category. The warrants were converted at a price of Rs. 13.05 each, including a premium of Rs. 3.05 each. The allotment has increased the company's paid-up equity share capital from Rs. 24,04,52,500.00 to Rs. 26,28,92,500.00.

Dipna Pharmachem Ltd, at its board meeting held on 29% November, 2025, considered and approved the allotment of 22,44,000 fully paid-up equity shares pursuant to the conversion of 22,44,000 convertible warrants. The warrants were allotted to Mr. Ashok Dilipkumar Jain and Ms. Kajal Ashok Jain, the allottees belonging to the ‘Non-Promoter Category’. The allotment was made at an issue price of Rs. 13.05/- each (including premium of Rs. 03.05/- each) on receipt of the balance amount, i.e., 75.00% of the issue price per warrant. The equity shares allotted upon the exercise of warrants on a preferential basis shall rank pari-passu with the existing equity shares of the Company in all respects. This has resulted in an increase in the paid-up equity share capital of the Company from Rs. 24,04,52,500.00/- to Rs. 26,28,92,500.00/-. The application for listing and trading approval of the newly issued and allotted equity shares will be made to the Stock Exchange in due course.

Dipna Pharmachem Ltd, a pharmaceutical trading company, has reported its financial results for the quarter ended on 30th September 2025. The company's profit from operations before exceptional items and tax stands at INR 190.65 Lakhs, representing a significant YoY growth of 190.65%. The company's revenue from operations stands at INR 906238 Lakhs, with a net profit of INR 141.10 Lakhs for the period. The company operates in one primary segment, Pharmaceutical Trading.